Skip to content

Transformation Application Research of Yi'ai Fuzheng No.II Decoction in the treatment of Advanced Triple Negative Breast Cancer

Transformation Application Research of Yi'ai Fuzheng No.II Decoction in the treatment of Advanced Triple Negative Breast Cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073932
Enrollment
Unknown
Registered
2023-07-25
Start date
2020-06-02
Completion date
Unknown
Last updated
2023-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Experimental group:Yi'ai Fuzheng No.II Decoction (twice a day, 100 mL each time) + conventional radiotherapy or/and chemotherapy
Control group:Conventional radiotherapy or/and chemotherapy

Sponsors

Zhongnan Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: All of the following criteria are met for inclusion 1) All are primary triple negative breast cancer and are diagnosed by pathology or cytology; 2) 18 years old = age = 70 years; 3) Patients with advanced triple negative breast cancer and with tumor metastasis, relapse or irregularities; 4) In order to facilitate observation, at least one lesion can be measured; 5) There are no serious organic or functional disorders such as heart, liver, kidney, brain, etc., without drugs and food allergies; 6) KPS score =70 points; 7) The expected life span =12 weeks; 8) Take effective contraceptive measures; 9) Voluntary signing of informed consent.

Exclusion criteria

Exclusion criteria: If the subject meets any of the following conditions will be exclusived 1) Do not meet the criteria of Inclusion; 2) It is known that those who are allergic to the component of medication in the study, or subject with allergies; 3) Starting from the opinions of researchers, some obvious diseases have excluded patients outside this study (for example: patients with irresistible diabetes or hypertension, patients with severe heart or lung disease); 4) Women who are in breastfeeding, pregnancy, or positive blood/urine pregnancy test; 5) Medical or psychological status does not allow patients to complete this study or signed an informed consent form; 6) Patients with other tumor history, in addition to those not recurred for more than 5 years; 7) Those who have mental illness affecting treament and follow-up compliance; 8) Participate in other clinical drug trial within 3 months before the study; 9) Researchers believe that it is not suitable to participate in this clinical trial.

Design outcomes

Primary

MeasureTime frame
Objective remission rate;

Secondary

MeasureTime frame
Disease control rate;Progression free survival;One-year survival rate;Overall survival;Traditional Chinese Medicine Syndrome Score;Life status assessment (KPS score);

Countries

China

Contacts

Public ContactYingwen Zhang

Zhongnan Hospital of Wuhan University

hhao3838@sina.com+86 153 2739 0419

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026